Search research articles
Contact Us
Filters
Showing results (111-120 of 198) with videos related to
Page
of 20
Sort By:
The Journal of Rheumatology
|
November 15, 2022
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Filip Van den Bosch, James Cheng-Chung Wei, Peter Nash, et al.
Rheumatology (Oxford, England)
|
December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
Peter Nash, Pascal Richette, Laure Gossec, et al.
RMD Open
|
March 26, 2024
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Laura C Coates, Laure Gossec, Miriam Zimmermann, et al.
Seminars in Arthritis and Rheumatism
|
June 11, 2020
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
Laura C Coates, Peter Nash, Tore K Kvien, et al.
Drug Safety
|
February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program
Philip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
RMD Open
|
November 9, 2023
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Christina Charles-Schoeman, Ernest Choy, Iain B McInnes, et al.
The Australasian Journal of Dermatology
|
July 28, 2023
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients
Peter Foley, Kurt Gebauer, John Sullivan, et al.
Rheumatology and Therapy
|
November 11, 2018
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Peter Nash, Laura C Coates, Roy Fleischmann, et al.
ACR Open Rheumatology
|
August 1, 2024
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials
Arthur Kavanaugh, Philip Mease, Laure Gossec, et al.
The Australasian Journal of Dermatology
|
January 22, 2013
Treatment goals for moderate to severe psoriasis: an Australian consensus
Christopher Baker, Alexandra Mack, Alan Cooper, et al.
Page
of 20
Search research articles
Search
Showing results (111-120 of 198) with videos related to
Sort By:
Page
of 20
The Journal of Rheumatology
|
November 15, 2022
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Filip Van den Bosch, James Cheng-Chung Wei, Peter Nash, et al.
Rheumatology (Oxford, England)
|
December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
Peter Nash, Pascal Richette, Laure Gossec, et al.
RMD Open
|
March 26, 2024
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Laura C Coates, Laure Gossec, Miriam Zimmermann, et al.
Seminars in Arthritis and Rheumatism
|
June 11, 2020
Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study
Laura C Coates, Peter Nash, Tore K Kvien, et al.
Drug Safety
|
February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program
Philip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
RMD Open
|
November 9, 2023
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Christina Charles-Schoeman, Ernest Choy, Iain B McInnes, et al.
The Australasian Journal of Dermatology
|
July 28, 2023
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients
Peter Foley, Kurt Gebauer, John Sullivan, et al.
Rheumatology and Therapy
|
November 11, 2018
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Peter Nash, Laura C Coates, Roy Fleischmann, et al.
ACR Open Rheumatology
|
August 1, 2024
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials
Arthur Kavanaugh, Philip Mease, Laure Gossec, et al.
The Australasian Journal of Dermatology
|
January 22, 2013
Treatment goals for moderate to severe psoriasis: an Australian consensus
Christopher Baker, Alexandra Mack, Alan Cooper, et al.
Page
of 20